FATE - NASDAQ

Fate Therapeutics, Inc.

Fate Therapeutics, Inc.

FATEยทNASDAQ

$2.57

-14%
HealthcareBiotechnology

Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. Its NK- and T-cell immuno-oncology programs under development include FT516 for the treatment of acute myeloid leukemia (AML) B-cell lymphoma, and advanced solid tumor; FT596 to treat B-cell lymphoma and chronic lymphocytic leukemia; FT538 to treat AML and multiple myeloma; FT576 to treat multiple myeloma; FT819 to treat hematologic malignancies and solid tumors; FT536 to treat solid tumors; and FT500 for the treatment of advanced solid tumors. The company has a collaboration and option agreement with Ono Pharmaceutical Co. Ltd. for the development and commercialization of two off-the-shelf iPSC-derived CAR T-cell product candidates; strategic research collaboration and license agreement with Juno Therapeutics, Inc. to screen for and identify small molecule modulators that enhance the therapeutic properties of genetically-engineered T-cell immunotherapies; and a collaboration and option agreement with Janssen Biotech, Inc. Fate Therapeutics, Inc. was incorporated in 2007 and is headquartered in San Diego, California.

StatementsValue Model

At a Glance

Live Snapshot
Market Cap$299.56M
EPS-1.1500
P/E Ratio-0.86
Earnings Date08/05/2026
Fate Therapeutics, Inc.

Fate Therapeutics, Inc. Fair Value Envelope

FATE ยท NASDAQ

Our analysis suggests that FATE has a fair value of HIDDEN per share in the Base Case projection. With shares currently trading at $2.57, this represents a potential HIDDEN relative to our calculated worth for Fate Therapeutics, Inc..

HIDDEN
Intrinsic Value
Current Price: $2.57

Owner Earnings Valuation Tool

Warren Buffett's Owner Earnings DCF analysis for intrinsic value calculation

Historical Financial Data

Base year metrics used for projections

$
%
$
%
$
$

Projection Settings

Forecast period and terminal assumptions

%
%

DCF Valuation Summary

Calculation flow from present value to intrinsic value per share

Present Value-$1.1B
+ Cash & Equivalents$46.6M
Firm Value-$1.1B
- Debt$77.8M
Equity Value-$1.2B
/ Shares Outstanding115,329,697B
DCF Value-$10
OVERVALUED BY 498%

Owner Earnings Projections

Operating Cash Flow - Maintenance CapEx = Owner Earnings

Metric
Year 1
Year 2
Year 3
Year 4
Year 5
Year 6
Year 7
Year 8
Year 9
Year 10
Operating Cash Flow
-$116.0M
-$126.9M
-$138.7M
-$151.7M
-$165.9M
-$181.4M
-$198.4M
-$217.0M
-$237.3M
-$259.5M
Maintenance CapEx
-$1.3M
-$1.4M
-$1.6M
-$1.7M
-$1.9M
-$2.0M
-$2.2M
-$2.4M
-$2.7M
-$2.9M
Owner Earnings
-$117.3M
-$128.3M
-$140.3M
-$153.4M
-$167.8M
-$183.5M
-$200.7M
-$219.4M
-$240.0M
-$262.4M
Discount Factor
0.926
0.857
0.794
0.735
0.681
0.630
0.583
0.540
0.500
0.463
Present Value
-$108.6M
-$110.0M
-$111.4M
-$112.8M
-$114.2M
-$115.6M
-$117.1M
-$118.6M
-$120.0M
-$121.6M
Terminal Value represents 0.0% of Enterprise Value
Negative Owner Earnings
This company generates negative free cash flow. Consider adjusting maintenance CapEx percentage or check the financial data.

Related Guides

Blog Categories

Continue your FATE research with focused valuation guides.

DCF Modeling

Improve assumptions for intrinsic value accuracy.

Forecasting

Calibrate growth paths and terminal value behavior.

WACC

Refine discount-rate logic for valuation quality.

Cost of Capital

Match risk profile to expected return assumptions.

Research Paths

Pick your next lens
1

Snapshot

Start with context, operating signals, and key market metrics.

2

Value Model

Stress test fair value across bear, base, and bull assumptions.

3

Statements

Validate revenue quality, margins, and balance sheet durability.

4

Earnings Call

Read management commentary and compare it with reported outcomes.

5

Dividends

Check payout sustainability and long-term distribution behavior.

6

Analyst Expectations

Review consensus spread and where estimate risk is concentrated.